The current financial score of Niagen Bioscience Inc is 7.07. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 27.19M, representing a year-over-year decrease of 19.99%, while its net profit experienced a year-over-year decrease of 125.62%.
The current valuation score of Niagen Bioscience Inc is 6.78. Its current P/E ratio is 8.86, which is 607.56% below the recent high of 62.72 and 41.57% above the recent low of 5.18.
The current earnings forecast score of Niagen Bioscience Inc is 8.67. The average price target is 11.75, with a high of 22.00 and a low of 8.50.
The current price momentum score of Niagen Bioscience Inc is 4.36. Currently, the stock price is trading between the resistance level at 2.49 and the support level at 1.84, making it suitable for range-bound swing trading.
The current institutional shareholding score of Niagen Bioscience Inc is 3.00. The latest institutional shareholding proportion is 38.95%, representing a quarter-over-quarter decrease of 23.33%.
The current risk assessment score of Niagen Bioscience Inc is 4.11. The company's beta value is 2.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.